MFSD2A

Across TCGA pan-cancer cohorts, MFSD2A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MFSD2A’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MFSD2A RNA is repressed in tumor relative to normal tissue. In most cancer types MFSD2A is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and LIHC are the cancer types where MFSD2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MFSD2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−2.956	<.001	9	view →
LUSC	Female	II,III,IV	−2.754	<.001	9	view →
LIHC	Female	II,III,IV	−4.223	<.001	8	view →
HNSC	Male	All	+1.200	<.001	7	view →
UCEC	All	II,III,IV	+1.476	<.001	6	view →
KICH	Female	All	−1.535	<.001	5	view →
PAAD	All	All	+2.447	<.001	4	view →
BRCA	All	II,III,IV	+0.487	.006	4	view →
CHOL	Female	All	−4.003	<.001	3	view →
PRAD	All	All	−1.731	<.001	2	view →
ESCA	All	All	+1.228	.034	1	view →
STAD	Female	III,IV	+0.725	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MFSD2A–LUAD

Open the LUAD breakdown →